# ProMIS Neurosciences (PMN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PMN
## Company Profile
- Ticker: PMN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada and listed in the U
- Tags: CNS
## Stock Data
- Close: 14.97 USD
- Market cap: 91022083.95 USD
- Last updated: 2026-08-11
## Business Overview
### Misfolded Protein Therapeutics
ProMIS Neurosciences develops antibodies that selectively recognize toxic misfolded protein species implicated in neurodegenerative disease.
### PMN310
PMN310 targets toxic amyloid-beta oligomers while seeking to avoid binding monomers and plaque, potentially reducing off-target immune effects.
### PRECISE-AD
The fully enrolled Phase 1b PRECISE-AD study evaluates PMN310 in patients with Alzheimer’s disease using safety, imaging, and biomarker measures.
## Why The Stock Is Moving

As of Aug 11, 2026, PMN closed up 1.70% at $14.97. No new same-company headline was identified in the current news window.

## Future Catalysts

- A blinded six-month PRECISE-AD interim analysis is expected in early third quarter 2026.
- Twelve-month topline PRECISE-AD data are expected in early 2027.

## Recent News
- 2026-08-03 20:00 EST — [ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026](https://biopharmsignal.com/news/PMN/promis-neurosciences-to-report-second-quarter-2026-financial-results-and-busines-ddaf05d1) — Source: ProMIS Neurosciences
- 2026-07-28 10:00 EST — [ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial](https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-positive-blinded-six-month-interim-safety-and-bioma-90dad1c6) — Source: ProMIS Neurosciences
- 2026-07-27 20:00 EST — [ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease](https://biopharmsignal.com/news/PMN/promis-neurosciences-to-host-webinar-to-discuss-upcoming-6-month-blinded-interim-36c2d083) — Source: ProMIS Neurosciences
- 2026-07-14 06:30 EST — [ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026](https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-targe-9106127e) — Source: ProMIS Neurosciences
- 2026-05-28 14:13 EST — [ProMIS Neurosciences to Participate in Upcoming Conferences in June](https://biopharmsignal.com/news/PMN/promis-neurosciences-to-participate-in-upcoming-conferences-in-june-00cd700a) — Source: ProMIS Neurosciences